Sosial helse, aktivitetsatferd og livskvalitet blant unge voksne kreftoverlevere
Sosial helse, aktivitetsatferd og livskvalitet blant unge voksne kreftoverlevere: En longitudinell studie
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality of life among ethnically and racially diverse adolescent and young adult (AYA) cancer patients aged 18-39 years. The study follows participants over four clinically significant timepoints in the first 12 months after diagnosis (baseline near diagnosis, mid treatment, near end of treatment, and 12 month follow up). At each timepoint, patients complete questionnaires and wear a wrist worn accelerometer for one week.
Studieoversikt
Status
Status
Forhold
Forhold
- Ondartet fast neoplasma
- Hodgkin lymfom
- Anatomisk stadium I brystkreft AJCC v8
- Anatomisk stadium IA brystkreft AJCC v8
- Anatomisk stadium IB brystkreft AJCC v8
- Anatomisk stadium II brystkreft AJCC v8
- Anatomisk stadium IIA brystkreft AJCC v8
- Anatomisk stadium IIB brystkreft AJCC v8
- Anatomisk stadium III brystkreft AJCC v8
- Anatomisk stadium IIIA brystkreft AJCC v8
- Anatomisk stadium IIIB brystkreft AJCC v8
- Anatomisk stadium IIIC brystkreft AJCC v8
- Prognostisk stadium I brystkreft AJCC v8
- Prognostisk stadium IA brystkreft AJCC v8
- Prognostisk stadium IB brystkreft AJCC v8
- Prognostisk stadium II brystkreft AJCC v8
- Prognostisk stadium IIA brystkreft AJCC v8
- Prognostisk stadium IIB brystkreft AJCC v8
- Prognostisk stadium III brystkreft AJCC v8
- Prognostisk stadium IIIA brystkreft AJCC v8
- Prognostisk stadium IIIB brystkreft AJCC v8
- Prognostisk stadium IIIC brystkreft AJCC v8
- Non-Hodgkin lymfom
- Stage III Livmor Corpus Cancer AJCC v8
- Klinisk stadium III kutant melanom AJCC v8
- Patologisk stadium IIIB kutant melanom AJCC v8
- Patologisk stadium IIIC kutant melanom AJCC v8
- Patologisk stadium IIID kutant melanom AJCC v8
- Klinisk stadium I kutant melanom AJCC v8
- Klinisk stadium IA kutant melanom AJCC v8
- Klinisk stadium IB kutant melanom AJCC v8
- Klinisk stadium II kutant melanom AJCC v8
- Klinisk stadium IIA kutant melanom AJCC v8
- Klinisk stadium IIB kutant melanom AJCC v8
- Klinisk stadium IIC kutant melanom AJCC v8
- Patologisk stadium I kutan melanom AJCC v8
- Patologisk stadium IA kutant melanom AJCC v8
- Patologisk stadium IB kutant melanom AJCC v8
- Patologisk stadium II kutant melanom AJCC v8
- Patologisk stadium IIA kutant melanom AJCC v8
- Patologisk stadium IIB kutant melanom AJCC v8
- Patologisk stadium IIC kutant melanom AJCC v8
- Patologisk stadium III kutant melanom AJCC v8
- Patologisk stadium IIIA kutant melanom AJCC v8
- Trinn III tykktarmskreft AJCC v8
- Trinn IIIA tykktarmskreft AJCC v8
- Trinn IIIB tykktarmskreft AJCC v8
- Stage IIIC tykktarmskreft AJCC v8
- Fase I tykktarmskreft AJCC v8
- Trinn II kolorektal kreft AJCC v8
- Fase IIA tykktarmskreft AJCC v8
- Stage IIB tykktarmskreft AJCC v8
- Stage IIC kolorektal kreft AJCC v8
- Fase I Livmorhalskreft AJCC v8
- Stadium IA Livmorhalskreft AJCC v8
- Stadium IA1 Livmorhalskreft AJCC v8
- Stadium IA2 Livmorhalskreft AJCC v8
- Stadium IB Livmorhalskreft AJCC v8
- Stadium IB1 Livmorhalskreft AJCC v8
- Stadium IB2 Livmorhalskreft AJCC v8
- Stadium II Livmorhalskreft AJCC v8
- Stadium IIA Livmorhalskreft AJCC v8
- Stadium IIA1 Livmorhalskreft AJCC v8
- Stadium IIA2 Livmorhalskreft AJCC v8
- Stadium IIB Livmorhalskreft AJCC v8
- Stadium III Livmorhalskreft AJCC v8
- Stadium IIIA Livmorhalskreft AJCC v8
- Stadium IIIB Livmorhalskreft AJCC v8
- Stadium IIIA Uterin Corpus Cancer AJCC v8
- Stadium IIIB Livmor Corpus Cancer AJCC v8
- Stage IIIC Livmor Corpus Cancer AJCC v8
- Stadium IIIC1 Uterin Corpus Cancer AJCC v8
- Stadium IIIC2 Uterin Corpus Cancer AJCC v8
- Ondartet hjerneneoplasma
- Stadium III Eggstokkreft AJCC v8
- Stadium IIIA Eggstokkreft AJCC v8
- Stadium IIIA1 Eggstokkreft AJCC v8
- Stadium IIIA2 Eggstokkreft AJCC v8
- Stadium IIIB Eggstokkreft AJCC v8
- Stadium IIIC Eggstokkreft AJCC v8
- Neoplasma i sentralnervesystemet
- Stage III differensiert skjoldbruskkjertelkarsinom AJCC v8
- Stage III skjoldbruskkjertel medullært karsinom AJCC v8
- Stage I Livmor Corpus Cancer AJCC v8
- Stage IA Livmor Corpus Cancer AJCC v8
- Stage IB Livmor Corpus Cancer AJCC v8
- Stage II Livmor Corpus Cancer AJCC v8
- Ondartet testikkelneoplasma
- Stadium II Eggstokkreft AJCC v8
- Stage IIA Eggstokkreft AJCC v8
- Stadium IIB Eggstokkreft AJCC v8
- Fase I Eggstokkreft AJCC v8
- Stadium IA Eggstokkreft AJCC v8
- Stadium IB Eggstokkreft AJCC v8
- Stage IC Eggstokkreft AJCC v8
- Ondartet benneoplasma
- Stadium I differensiert skjoldbruskkjertelcarcinom AJCC v8
- Stadium I medullært skjoldbruskkjertelkreft AJCC v8
- Stadium II differensiert skjoldbruskkjertelkreft AJCC v8
- Stadium II Medullært Carcinom i Skjoldbruskkjertelen AJCC v8
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. Characterize trajectories of social health over the course of cancer treatment and into early survivorship; II. Investigate longitudinal and potentially reciprocal associations between social health and activity behaviors (physical activity and sedentary time) and their relationship to quality of life; III. Examine whether gender, race/ethnicity, socioeconomic status, and symptom burden moderate these associations.
OUTLINE:
Patients complete surveys over 40 minutes and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Forente stater, 90033
- Los Angeles General Medical Center
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- MD Anderson Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients diagnosed and/or treated with cancer between ages 18-39 at University of Southern California (USC) hospitals.
Beskrivelse
Inclusion Criteria:
- Age 18-39 years at cancer diagnosis.
- Newly diagnosed (within past 3 months) with one of the following cancer types commonly seen in AYAs: testis, breast, thyroid, cervix, colorectal, brain/central nervous system, non Hodgkin lymphoma, uterine, melanoma, bones and joints, ovary, Hodgkin lymphoma, lung, or gastric cancer.
- Stage I-IV for solid tumors (AJCC 8th edition TNM staging) or I-IV for lymphomas (Ann Arbor staging).
- Receiving care at a participating USC affiliated hospital (USC Norris Comprehensive Cancer Center, Keck Hospital of USC, or Los Angeles General Medical Center) or MD Anderson Cancer Center.
- Clinician assessed expected survival greater than 12 months at time of diagnosis.
- Able to complete questionnaires and wear a wrist worn accelerometer.
- English or Spanish speaking.
Exclusion Criteria:
- Leukemia (excluded due to longer treatment duration and different care trajectory).
- Primary language other than English or Spanish.
- Cognitive or physical limitations that preclude completion of surveys or wearing an accelerometer.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_ONLY
- Tidsperspektiver: PROSPECTIVE
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Observational (actigraph, surveys)
Patients complete surveys and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months. |
Wear an actigraph GT3X-BT accelerometer Complete survey
Andre navn:
Complete survey |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in social role functioning
Tidsramme: Baseline up to 1 year
|
Assessed using the PROMIS Ability to Participate in Social Roles and Activities Short Form 4a, which measures limitations in participation in usual social roles and activities due to health (higher scores indicate better participation). |
Baseline up to 1 year
|
|
Change in perceived emotional support
Tidsramme: Baseline up to 1 year
|
Assessed using the PROMIS Emotional Support Short Form 4a, which measures perceived availability of people who provide emotional support, such as care, understanding, and someone to listen (higher scores indicate more emotional support). |
Baseline up to 1 year
|
|
Change in perceived informational support
Tidsramme: Baseline up to 1 year
|
Assessed using the PROMIS Informational Support Short Form 4a, which measures perceived availability of people who provide advice, information, and guidance (higher scores indicate more informational support). |
Baseline up to 1 year
|
|
Change in perceived instrumental support
Tidsramme: Baseline up to 1 year
|
Assessed using the PROMIS Instrumental Support Short Form 4a, which measures perceived availability of people who provide practical help and assistance with tasks (higher scores indicate more instrumental support). |
Baseline up to 1 year
|
|
Change in loneliness score
Tidsramme: Baseline up to 1 year
|
Assessed using the UCLA Loneliness Scale short form, which measures subjective feelings of loneliness and social disconnection (higher scores indicate greater loneliness). |
Baseline up to 1 year
|
|
Change in social anxiety symptoms
Tidsramme: Baseline up to 1 year
|
Assessed using the Mini Social Phobia Inventory (Mini SPIN), a brief validated measure of social anxiety and fear of social interactions (higher scores indicate greater social anxiety). |
Baseline up to 1 year
|
|
Change in social network density
Tidsramme: Baseline up to 1 year
|
Assessed using a study developed egocentric social network questionnaire in which participants list up to 10 important adult social contacts and indicate which contacts know each other; density is calculated as the proportion of possible ties that are present (higher values indicate a more densely connected network). |
Baseline up to 1 year
|
|
Change in proportion of supportive social ties
Tidsramme: Baseline up to 1 year
|
Assessed using a study developed egocentric social network questionnaire that measures whether each named social contact provides social support and encouragement for physical activity; the outcome is the proportion of social ties providing support (higher values indicate a more supportive network). |
Baseline up to 1 year
|
|
Change in frequency of social contact
Tidsramme: Baseline up to 1 year
|
Assessed using a study developed egocentric social network questionnaire that captures how often participants interact with each named social contact; the outcome is the average reported frequency of contact across alters (higher values indicate more frequent social contact). |
Baseline up to 1 year
|
|
Change in total daily physical activity
Tidsramme: Baseline up to 1 year
|
Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Raw data are converted to monitor independent movement summary (MIMS) units, and total daily physical activity is represented by average daily MIMS units across valid wear days (higher values indicate more physical activity). |
Baseline up to 1 year
|
|
Change in total daily sedentary time
Tidsramme: Baseline up to 1 year
|
Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Sedentary time is calculated from accelerometer data as average minutes per day spent in sedentary behavior (e.g., low movement periods while awake) across valid wear days (higher values indicate more sedentary time). |
Baseline up to 1 year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Quality of Life
Tidsramme: Baseline up to 1 year
|
Patient reported quality of life using Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health 10, assessed at baseline and 12 month follow up. This is a 10-item patient-reported questionnaire measuring general physical, mental, and social health. Most questions use a 1-to-5 point scale. Higher numerical values consistently represent better health or lower symptoms. The survey produces two separate scores: Global Physical Health (GPH) and Global Mental Health (GMH). Raw response values are summed and converted into standardized T-scores where a score of 50 represents the U.S. general population average (standard deviation of 10). |
Baseline up to 1 year
|
|
Symptom Burden
Tidsramme: Baseline up to 1 year
|
Symptom burden assessed using the MD Anderson Symptom Inventory (MDASI) at all four timepoints. This survey is a multi-symptom patient-reported outcome (PRO) measure used to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms. |
Baseline up to 1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: Kimberly Miller, PhD, University of Southern California
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i det endokrine systemet
- Beinsykdommer
- Muskel- og skjelettsykdommer
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Mannlige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Tarmsykdommer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Livmorsykdommer
- Kjønnssykdommer, kvinner
- Neoplasmer i endokrine kjertel
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Kolonsykdommer
- Sykdommer i eggstokkene
- Adnexal sykdommer
- Genitale neoplasmer, kvinnelige
- Gonadal lidelser
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Karsinom
- Livmor livmorhalssykdommer
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Lymfom
- Neoplasmer i nervesystemet
- Uterine neoplasmer
- Nevroendokrine svulster
- Neoplasmer, duktale, lobulære og medullære
- Karsinom, nevroendokrine
- Testikkelsykdommer
- Hemic og lymfatiske sykdommer
- Kolorektale neoplasmer
- Neoplasmer i eggstokkene
- Uterine cervikale neoplasmer
- Lymfom, Non-Hodgkin
- Hodgkins sykdom
- Neoplasmer i hjernen
- Neoplasmer i sentralnervesystemet
- Karsinom, medullær
- Testikkelneoplasmer
- Benneoplasmer
Andre studie-ID-numre
Andre studie-ID-numre
- 0S-20-10
- P30CA014089 (U.S. NIH-stipend/kontrakt)
- 0S-20-10 (Annen identifikator: USC / Norris Comprehensive Cancer Center)
- NCI-2021-05723 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- R37CA256867 (U.S. NIH-stipend/kontrakt)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .